AU2002345089A1 - Synthetic double stranded oligonucleotides for targeted inhibition of gene expression - Google Patents

Synthetic double stranded oligonucleotides for targeted inhibition of gene expression

Info

Publication number
AU2002345089A1
AU2002345089A1 AU2002345089A AU2002345089A AU2002345089A1 AU 2002345089 A1 AU2002345089 A1 AU 2002345089A1 AU 2002345089 A AU2002345089 A AU 2002345089A AU 2002345089 A AU2002345089 A AU 2002345089A AU 2002345089 A1 AU2002345089 A1 AU 2002345089A1
Authority
AU
Australia
Prior art keywords
gene expression
double stranded
stranded oligonucleotides
synthetic double
targeted inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2002345089A
Other versions
AU2002345089B2 (en
Inventor
Niki Gunkel
Jochen Huber
Sandra Neumann
Eugen Uhlmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10133858A external-priority patent/DE10133858A1/en
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Publication of AU2002345089A1 publication Critical patent/AU2002345089A1/en
Assigned to SANOFI-AVENTIS DEUTSCHLAND GMBH reassignment SANOFI-AVENTIS DEUTSCHLAND GMBH Request for Assignment Assignors: AVENTIS PHARMA DEUTSCHLAND GMBH
Application granted granted Critical
Publication of AU2002345089B2 publication Critical patent/AU2002345089B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

AU2002345089A 2001-07-12 2002-07-05 Synthetic double stranded oligonucleotides for targeted inhibition of gene expression Ceased AU2002345089B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10133858.9 2001-07-12
DE10133858A DE10133858A1 (en) 2001-07-12 2001-07-12 Synthetic double-stranded oligonucleotides for targeted inhibition of gene expression
PCT/EP2002/007480 WO2003008576A2 (en) 2001-07-12 2002-07-05 Synthetic double stranded oligonucleotides for targeted inhibition of gene expression

Publications (2)

Publication Number Publication Date
AU2002345089A1 true AU2002345089A1 (en) 2003-05-22
AU2002345089B2 AU2002345089B2 (en) 2007-04-05

Family

ID=7691504

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002345089A Ceased AU2002345089B2 (en) 2001-07-12 2002-07-05 Synthetic double stranded oligonucleotides for targeted inhibition of gene expression

Country Status (14)

Country Link
US (1) US8772469B2 (en)
EP (1) EP1409670B1 (en)
JP (1) JP4643906B2 (en)
AT (1) ATE484586T1 (en)
AU (1) AU2002345089B2 (en)
CA (1) CA2453301C (en)
CY (1) CY1111645T1 (en)
DE (2) DE10133858A1 (en)
DK (1) DK1409670T3 (en)
ES (1) ES2354062T3 (en)
IL (2) IL159758A0 (en)
MX (1) MXPA04000179A (en)
PT (1) PT1409670E (en)
WO (1) WO2003008576A2 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US9096636B2 (en) * 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US20040266706A1 (en) * 2002-11-05 2004-12-30 Muthiah Manoharan Cross-linked oligomeric compounds and their use in gene modulation
WO2003064625A2 (en) 2002-02-01 2003-08-07 Sequitur, Inc. Oligonucleotide compositions with enhanced efficiency
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
US9771578B2 (en) * 2002-11-05 2017-09-26 Ionis Pharmaceuticals, Inc. Phosphorous-linked oligomeric compounds and their use in gene modulation
EP1560840B1 (en) 2002-11-05 2015-05-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
US9827263B2 (en) * 2002-11-05 2017-11-28 Ionis Pharmaceuticals, Inc. 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
WO2005121372A2 (en) * 2004-06-03 2005-12-22 Isis Pharmaceuticals, Inc. Double strand compositions comprising differentially modified strands for use in gene modulation
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
US20100292301A1 (en) * 2007-02-28 2010-11-18 Elena Feinstein Novel sirna structures
KR20100068422A (en) * 2007-10-09 2010-06-23 콜리 파마슈티칼 게엠베하 Immune stimulatory oligonucleotide analogs containing modified sugar moieties
WO2009090639A2 (en) * 2008-01-15 2009-07-23 Quark Pharmaceuticals, Inc. Sirna compounds and methods of use thereof
CN102016036B (en) 2008-02-11 2015-04-08 阿克赛医药公司 Modified RNAi polynucleotides and uses thereof
WO2010008582A2 (en) 2008-07-18 2010-01-21 Rxi Pharmaceuticals Corporation Phagocytic cell drug delivery system
EP3336188B1 (en) 2008-09-22 2020-05-06 Phio Pharmaceuticals Corp. Reduced size self-delivering rnai compounds
WO2010059226A2 (en) 2008-11-19 2010-05-27 Rxi Pharmaceuticals Corporation Inhibition of map4k4 through rnai
US9493774B2 (en) 2009-01-05 2016-11-15 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAi
US9745574B2 (en) 2009-02-04 2017-08-29 Rxi Pharmaceuticals Corporation RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
RU2615143C2 (en) 2010-03-24 2017-04-04 Адвирна Self-delivered rnai compounds of reduced size
IL265674B2 (en) 2010-03-24 2024-05-01 Phio Pharm Corp Rna interference in dermal and fibrotic indications
CN106074591B (en) 2010-03-24 2020-01-14 菲奥医药公司 RNA interference in ocular symptoms
JP6772062B2 (en) 2013-12-02 2020-10-21 フィオ ファーマシューティカルズ コーポレーションＰｈｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐ． Cancer immunotherapy
US11279934B2 (en) 2014-04-28 2022-03-22 Phio Pharmaceuticals Corp. Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
CN107073294A (en) 2014-09-05 2017-08-18 阿克赛医药公司 Use the method for targeting TYR or MMP1 exonuclease treatment aging and skin disorder
WO2017007825A1 (en) 2015-07-06 2017-01-12 Rxi Pharmaceuticals Corporation Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
EP3862005A1 (en) 2015-07-06 2021-08-11 Phio Pharmaceuticals Corp. Nucleic acid molecules targeting superoxide dismutase 1 (sod1)
US11021707B2 (en) 2015-10-19 2021-06-01 Phio Pharmaceuticals Corp. Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA
MA45470A (en) 2016-04-01 2019-02-06 Avidity Biosciences Llc KRAS NUCLEIC ACIDS AND THEIR USES
MA45328A (en) 2016-04-01 2019-02-06 Avidity Biosciences Llc NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF
MA45469A (en) 2016-04-01 2019-02-06 Avidity Biosciences Llc BETA-CATENIN NUCLEIC ACIDS AND THEIR USES
MA45349A (en) 2016-04-01 2019-02-06 Avidity Biosciences Llc EGFR NUCLEIC ACIDS AND THEIR USES
MX2020005860A (en) 2017-12-06 2020-09-09 Avidity Biosciences Inc Compositions and methods of treating muscle atrophy and myotonic dystrophy.
CA3157486A1 (en) * 2019-10-11 2021-04-15 Alnylam Pharmaceuticals, Inc. Modified oligonucleotides
JP2023537798A (en) 2020-03-19 2023-09-06 アビディティー バイオサイエンシーズ，インク． Compositions and methods for treating facioscapulohumeral muscular dystrophy
WO2023220744A2 (en) * 2022-05-13 2023-11-16 Alnylam Pharmaceuticals, Inc. Single-stranded loop oligonucleotides

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3717436A1 (en) * 1987-05-23 1988-12-08 Hoechst Ag METHOD FOR PRODUCING DOUBLE-STRANDED DNA
US4924624A (en) 1987-10-22 1990-05-15 Temple University-Of The Commonwealth System Of Higher Education 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
US6033909A (en) * 1992-01-22 2000-03-07 Hoechst Aktiengesellschaft Oligonucleotide analogs, their preparation and use
NZ255028A (en) * 1992-07-02 1997-03-24 Hybridon Inc Antisense oligonucleotides resistant to nucleolytic degradation
US5646042A (en) * 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
US5583032A (en) * 1992-10-21 1996-12-10 The Cleveland Clinic Foundation And National Institutes Of Health Method of cleaving specific strands of RNA
US5532130A (en) * 1993-07-20 1996-07-02 Dyad Pharmaceutical Corporation Methods and compositions for sequence-specific hybridization of RNA by 2'-5' oligonucleotides
US5886165A (en) * 1996-09-24 1999-03-23 Hybridon, Inc. Mixed backbone antisense oligonucleotides containing 2'-5'-ribonucleotide- and 3'-5'-deoxyribonucleotides segments
US6794499B2 (en) * 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US6010907A (en) * 1998-05-12 2000-01-04 Kimeragen, Inc. Eukaryotic use of non-chimeric mutational vectors
US6004804A (en) * 1998-05-12 1999-12-21 Kimeragen, Inc. Non-chimeric mutational vectors
AU5314999A (en) * 1998-07-14 2000-02-07 Isis Pharmaceuticals, Inc. Modified oligonucleotides
AU3369900A (en) 1999-02-19 2000-09-04 General Hospital Corporation, The Gene silencing
US6316194B1 (en) * 1999-12-16 2001-11-13 Ribotargets Methods and kits for discovery of RNA-binding antimicrobials
WO2002044321A2 (en) * 2000-12-01 2002-06-06 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Rna interference mediating small rna molecules

Similar Documents

Publication Publication Date Title
AU2002345089A1 (en) Synthetic double stranded oligonucleotides for targeted inhibition of gene expression
AU2002329667A1 (en) Specific inhibition of gene expression by small double stranded rnas
WO2003008576A3 (en) Synthetic double stranded oligonucleotides for targeted inhibition of gene expression
HUP0103571A3 (en) Characterisation of gene function using double stranded rna inhibition
AU2002339348A1 (en) Inhibition of STAT-1
AU2002251266A1 (en) Inhibitors of akt activity
AU2002259196A1 (en) Gene expression profiling
AU2003297474A1 (en) Methods of inhibiting gene expression by rna interference
AU2002253836A1 (en) Aptamer-mediated regulation of gene expression
AU2003287254A1 (en) Inhibition of gene expression using rna interfering agents
AU2002314997A1 (en) Methods for low background cloning of dna using long oligonucleotides
AU2003299864A1 (en) Sirna compounds and methods for the downregulation of gene expression
AU2003222197A1 (en) Inhibition of rna function
AU1548401A (en) Use of disease-associated gene
AU2003239864A1 (en) Antisense moodulation of kinesin-like 1 expression
AU2002360394A1 (en) Facilitation of rna interference
AU2002325305A1 (en) Novel oligoribonucleotide derivatives for the targeted inhibition of gene expression
AU2002219992A1 (en) Targeted regulation of gene expression
AU2003285583A1 (en) Oligonucleotide guided analysis of gene expression
AU2003272498A1 (en) Fragmentation of dna
AU2002345658A1 (en) Methods for targeted expression of therapeutic nucleic acid
AU2003256931A1 (en) USES OF CIRCADIAN GENE mPER2
AU2003253197A1 (en) Targeted gene modification by single-stranded dna oligonucleotides
AU2003276130A1 (en) Epididymis-specific gene as potential contraceptive target
AU2003282564A1 (en) Gene profiling of single or multiple cells